Matches in SemOpenAlex for { <https://semopenalex.org/work/W1596694562> ?p ?o ?g. }
- W1596694562 endingPage "436" @default.
- W1596694562 startingPage "425" @default.
- W1596694562 abstract "Retigabine [RTG (international nonproprietary name); ezogabine (EZG; U.S. adopted name)] is a first-in-class antiepileptic drug (AED) that reduces neuronal excitability by enhancing the activity of KCNQ (K(v)7) potassium (K(+)) channels. RTG/EZG has recently been approved by the European Medicines Agency and the U.S. Food and Drug Administration as adjunctive therapy in adults with partial-onset seizures. In this review we discuss the activity that RTG/EZG has demonstrated across a broad spectrum of in vitro/in vivo animal models of seizures, including generalized tonic-clonic, primary generalized (absence), and partial seizures, in addition to the compound's ability to resist and block the occurrence of seizures induced by a range of stimuli across different regions of the brain. The potency of RTG/EZG in models refractory to several conventional AEDs and the work done to assess antiepileptogenesis and neuroprotection are discussed. Studies that have evaluated the central nervous system side effects of RTG/EZG in animals are reviewed in order to compare these effects with adverse events observed in patients with epilepsy. Based on its demonstrated effect in a number of animal epilepsy models, the synergistic and additive activity of RTG/EZG with other AEDs supports its potential use in therapeutic combinations for different seizure types. The distinct mechanism of action of RTG/EZG from those of currently available AEDs, along with its broad preclinical activity, underscores the key role of KCNQ (K(v)7) K(+) channels in neuronal excitability, and further supports the potential efficacy of this unique molecule in the treatment of epilepsy." @default.
- W1596694562 created "2016-06-24" @default.
- W1596694562 creator A5003244031 @default.
- W1596694562 creator A5037742036 @default.
- W1596694562 creator A5037876897 @default.
- W1596694562 creator A5041773724 @default.
- W1596694562 creator A5042973942 @default.
- W1596694562 creator A5057547399 @default.
- W1596694562 creator A5068699786 @default.
- W1596694562 creator A5088706930 @default.
- W1596694562 date "2012-01-05" @default.
- W1596694562 modified "2023-10-11" @default.
- W1596694562 title "The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use" @default.
- W1596694562 cites W1500064345 @default.
- W1596694562 cites W1534647496 @default.
- W1596694562 cites W1547367931 @default.
- W1596694562 cites W1573130913 @default.
- W1596694562 cites W1585880958 @default.
- W1596694562 cites W1590926633 @default.
- W1596694562 cites W1801117657 @default.
- W1596694562 cites W19003993 @default.
- W1596694562 cites W1934871911 @default.
- W1596694562 cites W1965600102 @default.
- W1596694562 cites W1966917036 @default.
- W1596694562 cites W1970786328 @default.
- W1596694562 cites W1972382865 @default.
- W1596694562 cites W1973027891 @default.
- W1596694562 cites W1983021935 @default.
- W1596694562 cites W1983872098 @default.
- W1596694562 cites W1987357626 @default.
- W1596694562 cites W1988473559 @default.
- W1596694562 cites W1988587145 @default.
- W1596694562 cites W1990039788 @default.
- W1596694562 cites W1991845725 @default.
- W1596694562 cites W1995410958 @default.
- W1596694562 cites W1996501896 @default.
- W1596694562 cites W1996892862 @default.
- W1596694562 cites W1997544686 @default.
- W1596694562 cites W1998280293 @default.
- W1596694562 cites W2005134750 @default.
- W1596694562 cites W2010973036 @default.
- W1596694562 cites W2011454114 @default.
- W1596694562 cites W2011505692 @default.
- W1596694562 cites W2012443515 @default.
- W1596694562 cites W2012765989 @default.
- W1596694562 cites W2013844266 @default.
- W1596694562 cites W2014906362 @default.
- W1596694562 cites W2016955666 @default.
- W1596694562 cites W2019971652 @default.
- W1596694562 cites W2020794407 @default.
- W1596694562 cites W2033494215 @default.
- W1596694562 cites W2034953323 @default.
- W1596694562 cites W2035175313 @default.
- W1596694562 cites W2039060590 @default.
- W1596694562 cites W2039578096 @default.
- W1596694562 cites W2041396835 @default.
- W1596694562 cites W2042091223 @default.
- W1596694562 cites W2044984191 @default.
- W1596694562 cites W2045267605 @default.
- W1596694562 cites W2046473892 @default.
- W1596694562 cites W2046799089 @default.
- W1596694562 cites W2052000573 @default.
- W1596694562 cites W2055766784 @default.
- W1596694562 cites W2056289534 @default.
- W1596694562 cites W2059836016 @default.
- W1596694562 cites W2062463079 @default.
- W1596694562 cites W2063464796 @default.
- W1596694562 cites W2067898834 @default.
- W1596694562 cites W2070032514 @default.
- W1596694562 cites W2071335594 @default.
- W1596694562 cites W2074162571 @default.
- W1596694562 cites W2077977641 @default.
- W1596694562 cites W2087291581 @default.
- W1596694562 cites W2088393247 @default.
- W1596694562 cites W2090551991 @default.
- W1596694562 cites W2095000729 @default.
- W1596694562 cites W2100283245 @default.
- W1596694562 cites W2104981570 @default.
- W1596694562 cites W2111187306 @default.
- W1596694562 cites W2114499550 @default.
- W1596694562 cites W2120091670 @default.
- W1596694562 cites W2120745993 @default.
- W1596694562 cites W2121382073 @default.
- W1596694562 cites W2124201800 @default.
- W1596694562 cites W2125362348 @default.
- W1596694562 cites W2137263523 @default.
- W1596694562 cites W2143998666 @default.
- W1596694562 cites W2148662056 @default.
- W1596694562 cites W2148945706 @default.
- W1596694562 cites W2153629931 @default.
- W1596694562 cites W2156711983 @default.
- W1596694562 cites W2164753853 @default.
- W1596694562 cites W2305659333 @default.
- W1596694562 cites W2333507299 @default.
- W1596694562 cites W2689267561 @default.
- W1596694562 cites W4206810002 @default.
- W1596694562 cites W4242041782 @default.
- W1596694562 doi "https://doi.org/10.1111/j.1528-1167.2011.03364.x" @default.